MRK - Merck & Co Inc
SNP 500DOW 30


Revenue was Negative


based on last 5 year data.
Income Statement is WEAK
Revenue was Negative
Operating Income turning Positive
Net Income Growth is -69.86%
Earnings Per Share (EPS) Growth is -70.05%
Net Margin is 4.42%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 1.38
Debt Ratio is 0.29
Current Debt to Net Income Ratio is 0.19
Total Debt to Total Assets Ratio is 0.33
Cash Flow is MODERATE
Cash from Operations Growth is -13.01%
Capital Expenditure is High
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Merck & Co Inc (MRK) -
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of its mission to save and improve lives. It demonstrates its commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals - including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases - as we aspire to be the premier research-intensive biopharmaceutical company in the world.
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
Employees - 69,000



Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2023 and future.